Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents

SARS-CoV-2康复者长期随访和疫苗接种期间刺突蛋白和核衣壳特异性免疫的动态变化

阅读:1
作者:Nina Koerber # ,Alina Priller # ,Sarah Yazici # ,Tanja Bauer # ,Cho-Chin Cheng ,Hrvoje Mijočević ,Hannah Wintersteller ,Samuel Jeske ,Emanuel Vogel ,Martin Feuerherd ,Kathrin Tinnefeld ,Christof Winter ,Jürgen Ruland ,Markus Gerhard ,Bernhard Haller ,Catharina Christa ,Otto Zelger ,Hedwig Roggendorf ,Martin Halle ,Johanna Erber ,Paul Lingor ,Oliver Keppler ,Dietmar Zehn ,Ulrike Protzer # ,Percy A Knolle #

Abstract

Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we characterize the dynamics of anti-viral immunity during long-term follow-up and after BNT162b2 mRNA-vaccination in convalescents after asymptomatic or mild SARS-CoV-2 infection. Virus-specific and virus-neutralizing antibody titers rapidly declined in convalescents over 9 months after infection, whereas virus-specific cytokine-producing polyfunctional T cells persisted, among which IL-2-producing T cells correlated with virus-neutralizing antibody titers. Among convalescents, 5% of individuals failed to mount long-lasting immunity after infection and showed a delayed response to vaccination compared to 1% of naïve vaccinees, but successfully responded to prime/boost vaccination. During the follow-up period, 8% of convalescents showed a selective increase in virus-neutralizing antibody titers without accompanying increased frequencies of circulating SARS-CoV-2-specific T cells. The same convalescents, however, responded to vaccination with simultaneous increase in antibody and T cell immunity revealing the strength of mRNA-vaccination to increase virus-specific immunity in convalescents.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。